Menü
You have to log in or sign up before you can proceed.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Evolva delivers strong results with 57% revenue growth and increasing margins
Evolva delivers strong results with 57% revenue growth and increasing margins
Evolva delivers strong results with 57% revenue growth and increasing margins
Humana, Feeding America® Partner to Support Mobile Food Pantries: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana, Feeding America® Partner to Support Mobile Food Pantries


Leading health and wellness company Humana Inc. (NYSE: HUM) is helping to address food insecurity with a $625,000 grant to Feeding America, supporting mobile food pantries in nine states.


This

Valbiotis gibt Roadmap für 2023 bekannt: ein entscheidendes Jahr für die Umsetzung der klinischen, industriellen und kommerziellen Strategie : https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis gibt Roadmap für 2023 bekannt: ein entscheidendes Jahr für die Umsetzung der klinischen, industriellen und kommerziellen Strategie


Aufsichtsrechtliche Meldung:



Valbiotis (FR0013254851 – ALVAL, PEA-KMU-qualifiziert), ein kommerziell orientiertes Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlichen

ICON Issues Financial Guidance for Full Year 2023: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON Issues Financial Guidance for Full Year 2023


ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2023. For the

Inogen Achieves Regulatory Milestones to Support Current and Future Products: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen Achieves Regulatory Milestones to Support Current and Future Products


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has achieved regulatory milestones in the

Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Inogen Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Within Company Expectations: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Within Company Expectations


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
EQS-News: Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
EQS-News: Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
EQS-News: BRAIN Biotech AG: BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform
EQS-News: BRAIN Biotech AG: BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform
EQS-News: BRAIN Biotech AG: BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform
EQS-Adhoc: BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)
EQS-Adhoc: BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)
EQS-Adhoc: BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)
Valbiotis Announces Its Roadmap for 2023: a Pivotal Year in the Execution of Its Clinical, Industrial and Commercial Strategy: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis Announces Its Roadmap for 2023: a Pivotal Year in the Execution of Its Clinical, Industrial and Commercial Strategy


Regulatory News:



Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating

Agilent Authorizes $2 Billion Share Repurchase Program: https://www.flatex.at/fileadmin/dateien_flatex/images/logos/logo-claim_flatex-at_positiv_rgb.png
Agilent Authorizes $2 Billion Share Repurchase Program


Agilent Technologies Inc. (NYSE: A) today announced that its board of directors has approved a new share repurchase program. The 2023 program authorizes the purchase of up to $2 billion of the

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10th, at 10:30 a.m. PST

Puma Biotechnology Releases Updated Corporate Presentation: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Releases Updated Corporate Presentation


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, will refer

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook


DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31

Dexcom Appoints Teri Lawver as Chief Commercial Officer: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Appoints Teri Lawver as Chief Commercial Officer


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the newly created role of chief

Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update


Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2022. Novocure is a global oncology company

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-Adhoc: Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea®1, in the United States
EQS-Adhoc: Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea®1, in the United States
EQS-Adhoc: Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea®1, in the United States
EQS-News: BRAIN Biotech AG: Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site
EQS-News: BRAIN Biotech AG: Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site
EQS-News: BRAIN Biotech AG: Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site
QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies
QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies


QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced it has completed the acquisition of Verogen, a leader in the use of next-generation sequencing (NGS) technologies to drive the

QIAGEN schließt Übernahme von Verogen ab und stärkt führende Position im Bereich Forensik mit NGS-Technologien
QIAGEN schließt Übernahme von Verogen ab und stärkt führende Position im Bereich Forensik mit NGS-Technologien


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute den Abschluss der Übernahme von Verogen bekannt gegeben – einem führenden Unternehmen im Bereich Next-Generation-Sequencing-Technologien

IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S


IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat